Since 2005, millions of HIV-positive patients in low- and middle-income countries have received lifesaving antiretroviral therapy through Gilead’s voluntary licensing program for tenofovir. More recently this approach has been expanded to sofosbuvir for the treatment of Hepatitis C.
To date, a rigorous evaluation has not been done to understand this process of making medicines available.
Boston University will be evaluating Gilead’s Global Access program over the course of 2019.
Key activities
- Review of peer-review and grey literature about Gilead’s voluntary licensing (VL) program
- Discussion with international experts about the achievements and challenges of VL program
- Analysis of publicly available procurement data to assess the program’s achievements
Evaluation of Gilead Access Program 